ArticleEuropean journal of clinical investigation1994
Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).
Article in European journal of clinical investigation, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The relationship between Lp(a) and CVD outcomes: a systematic review.Lipids in health and disease · 2016Pooled it
- Pooled it
- Pooled it
- The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.European journal of epidemiology · 2007Pooled it
- Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis.PLoS medicine · 2005Pooled it
- Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial.European heart journal · 2017Trial
- Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.Nature clinical practice. Cardiovascular medicine · 2009Trial
- The influence of triglyceride and low-density-lipoprotein target levels on microcirculation: Is there a difference?Heliyon · 2024Article
- Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension?International journal of molecular sciences · 2023Review
- Evaluation of coagulation parameters in patients with parathyroid adenoma.Scientific reports · 2020Article
- Lipoprotein(a): the underutilized risk factor for cardiovascular disease.Global cardiology science & practice · 2019Article
- Wheat Flour, Enriched with γ-Oryzanol, Phytosterol, and Ferulic Acid, Alleviates Lipid and Glucose Metabolism in High-Fat-Fructose-Fed Rats.Nutrients · 2019Article
- Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).Clinical research in cardiology supplements · 2017Review
- Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.Journal of lipid research · 2016Review
- HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?Blood transfusion = Trasfusione del sangue · 2016Article
- Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.Clinical research in cardiology supplements · 2015Article
- High prevalence of raised lipoprotein(a) in patients with refractory angina.Global cardiology science & practice · 2015Article
- ENDOTHELIN-1 SYTEM ACTIVITY IN ADULTS WITH BORDERLINE HIGH LDL-CHOLESTEROL.Artery research · 2014Article
- Relationship between Lipoprotein(a) and Thyroid Hormones in Hypothyroid Patients.Journal of clinical and diagnostic research : JCDR · 2014Article
- The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina.Global cardiology science & practice · 2014Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on pathophysiological findings Lp(a) is considered to be a cardiovascular risk factor. The Göttingen Risk Incidence and Prevalence Study (GRIPS) provides the possibility to evaluate this impact of Lp(a) on the basis of a large prospective cohort study. GRIPS included 6002 men, aged 40-59.9 years at baseline. Data of a 5 year follow-up period is now available for > 95% of the study participants. Multivariate logistic regression models for the estimation of MI risk confirm Lp(a) as an important risk factor, ranking fifth behind LDL cholesterol, family history of MI, plasma fibrinogen and HDL cholesterol (inversely related). The GRIPS data strongly support strategies for the identification and treatment of persons at increased MI risk which focus on LDL cholesterol. However, Lp(a) and fibrinogen have to be seriously considered as additional risk factors and should be included in diagnostic panels for the estimation of MI risk.
Indexed as
Identifiers
7957500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.